Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
275M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
16.8M
-
Shares change
-
-1.52M
-
Total reported value, excl. options
-
$110M
-
Value change
-
-$16.4M
-
Put/Call ratio
-
1.51
-
Number of buys
-
40
-
Number of sells
-
-22
-
Price
-
$6.52
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q1 2022
77 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value as of Q1 2022.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.8M shares
of 275M outstanding shares and own 6.13% of the company stock.
Largest 10 shareholders include FMR LLC (3.29M shares), BlackRock Inc. (2.19M shares), Nantahala Capital Management, LLC (1.33M shares), FRANKLIN RESOURCES INC (1.3M shares), Artal Group S.A. (1.04M shares), VANGUARD GROUP INC (1.01M shares), Sands Capital Ventures, LLC (725K shares), TimesSquare Capital Management, LLC (666K shares), Alphabet Inc. (641K shares), and TYBOURNE CAPITAL MANAGEMENT (HK) LTD (500K shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.